Search

everythinglearnresearchcommunity

for

Search:↓

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

User discusses Pyrilutamide's effectiveness for hair loss, needing more time for results. Others suggest waiting 6-12 months and ask about side effects.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

Finasteride, dutasteride, saw palmetto, caffeine, spironolactone, acetyltetrapeptides, tea tree oil, hydrocortisone, zinc pyrithione, latanoprost, melatonin, marine protein supplements, PRP, microneedling, and valproate are discussed as treatments for hair loss. DHT reduction and inflammation control are key strategies.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

Two different experiences of using Pyrilutamide, a hair loss treatment, which caused headaches that took around a week to subside in both cases. Other users offered insight into their own experiences with the treatment or suggested alternate treatments such as RU58841 and Minoxidil.

Tretinoin combined with minoxidil is effective for hair loss and can be used once daily. The user seeks a compounding pharmacy to mix these without finasteride.

RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.

Pyrilutamide shows promising hair growth results, but skepticism exists due to potential biases and lack of blinding in the study. Concerns about side effects and legitimacy of the product persist, with comparisons to finasteride and discussions on post-finasteride syndrome.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The user is considering using these alongside Pyrilutamide 0.9%.

Bryan Johnson uses Dutasteride, Latanoprost, Minoxidil with Tretinoin, and other unproven treatments, while Derek uses Finasteride, Minoxidil, Nizoral, RU58841, and Castor Oil. Kevin uses Finasteride, Minoxidil, RU58841, and Alfatradiol, but is against Nizoral and microneedling, preferring Tretinoin for absorption.

The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.